Reuters -- Delcath Systems Inc said U.S. health regulators granted an orphan drug status to doxorubicin, a chemotherapy agent, for the treatment of primary liver cancer, sending its shares up 48 percent.
Reuters -- Delcath Systems Inc said U.S. health regulators granted an orphan drug status to doxorubicin, a chemotherapy agent, for the treatment of primary liver cancer, sending its shares up 48 percent.
